SEC Form 4 · accession 0000920465-15-000066
LA JOLLA PHARMACEUTICAL CO · LJPC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lakhmir S Chawla
Officer — Chief Medical Officer
Period of report
Aug 31, 2015
Accepted (ET)
Sep 2, 2015 · 9:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920465
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $35.58 | Aug 31, 2015 | A | 60,000 | A | — | Aug 31, 2025 | Common Stock | 60,000 | 60,000 | D |
| Stock Option (Right to Buy)F2,F3 | $35.58 | Aug 31, 2015 | A | 40,000 | A | — | Aug 31, 2025 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1This option represents a right to purchase a total of 60,000 shares of the Issuer's Common Stock, which shall vest in 48 equal monthly installments starting on 9/30/2015.
- F2Option vests and becomes exercisable upon the achievement of certain performance-related goals in 2016. The timing for the achievement of such goals determines the number of shares underlying the award.
- F3Represents the maximum number of shares of common stock underlying the option grant, with the actual number of shares issuable upon exercise to be determined based on the timing of the achievement of the vesting criteria described in footnote 2.